Success Metrics

Clinical Success Rate

93.3%

Based on 14 completed trials

Completion Rate

93%(14/15)

Active Trials

1(5%)

Results Posted

0%(0 trials)

Terminated

1(5%)

Phase Distribution

Ph phase_3

10%

Ph not_applicable

75%

Ph phase_2

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution19 total trials

Phase 2Efficacy & side effects

2(10.5%)

Phase 3Large-scale testing

2(10.5%)

N/ANon-phased studies

15(78.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

14 of 16 finished

Non-Completion Rate

12.5%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(14)

Terminated(2)

Other(3)

Detailed Status

Completed14

unknown3

Terminated1

Active, not recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

93.3%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (10.5%)

Phase 32 (10.5%)

N/A15 (78.9%)

Trials by Status

completed1470%

terminated15%

unknown315%

active_not_recruiting15%

withdrawn15%

Recent Activity

1 active trials

Showing 5 of 20

active_not_recruitingnot_applicable

Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula

NCT02410057

View all 20 trials

Clinical Trials (20)

Showing 20 of 20 trials

NCT06686433Not Applicable

The Impact of a Novel Infant Formula on Immunity, Gut Health and Growth

Active Not Recruiting

NCT04066413Not Applicable

Growth and Tolerance Trial on Infant Formula With HMO

Terminated

NCT03456934Not Applicable

Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease

Completed

NCT02598817

Acceptability and Gastrointestinal Tolerance of a High-Sn-2 Infant Formula

Completed

NCT02410057Not Applicable

Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula

Unknown

NCT03062995Phase 3

A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on the Development of Allergic Manifestations in Infants at High Risk of Developing Allergy

Withdrawn

NCT03067714Phase 3

A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbiota Composition and Clinical Effectiveness in Infants at High Risk of Developing Allergy

Completed

NCT02670863Not Applicable

Safety and Efficacy Study

Completed

NCT03710551Not Applicable

Happy Smooth Study

Completed

NCT01094080Not Applicable

Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health

Completed

NCT02469402Not Applicable

Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein Content and Improved Protein Quality

Completed

NCT02094547Not Applicable

A Neurocognitive and Immunological Study of a New Formula for Healthy Infants

Unknown

NCT03062761Phase 2

A Clinical Study to Investigate the Effects of an Infant Formula Containing Partially Hydrolysed Proteins on Growth, Safety and Tolerance in Healthy Term Infants

Completed

NCT00716105Not Applicable

Effect of the Level of Dietary Protein on Infant Growth

Completed

NCT00820833Not Applicable

Effect of Formula on Growth of Infants From Overweight or Obese Mothers

Completed

NCT02111837Not Applicable

Effects of Specific Lipid Fractions-enriched Infant Formulae

Completed

NCT00937014Not Applicable

Assessment of Growth of Infants Fed a New Formula